Protagonist Therapeutics

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

NEWARK, Calif., Dec. 2, 2021 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced the selection of PN-235 (JNJ-77242113) as the final candidate for all clinical studies in multiple indications based on intervention of the Interleukin-23 (IL-23) pathway, under the Company's collaboration with Janssen Biotech, Inc. (Janssen).

Protagonist Therapeutics Announces the Selection of Oral Peptide PN-235 into Phase 2 Clinical Development Program for Multiple Indications

NEWARK, Calif., Nov. 15, 2021 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced results from a Phase 2a study in which rusfertide, an investigational new drug, is being evaluated for the treatment of hereditary hemochromatosis (HH).

Protagonist Therapeutics Announces Positive Phase 2a Data Supporting the Potential Use of Rusfertide as a First-in-Class Therapy in Hereditary Hemochromatosis

NEWARK, Calif., Nov. 11, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V.

Protagonist Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences

Following huge swings over the last two months, the biotech stock is now up 67% year to date.

Why Protagonist Therapeutics Stock Skyrocketed 80.2% Last Month

NEWARK, Calif., Nov. 4, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that two abstracts highlighting updated data from its Phase 2 study of rusfertide in polycythemia vera (PV) have been selected for oral presentations at the American Society of Hematology (ASH) 2021 Annual Meeting taking place December 11-14, 2021.

Protagonist Therapeutics Announces Updated Data from Phase 2 Study of Rusfertide in Polycythemia Vera Selected for Oral Presentations at the ASH 2021 Annual Meeting

NEWARK, Calif., Nov. 3, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today reported its financial results for the third quarter ended September 30, 2021 and provided a corporate update.

Protagonist Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

WiMi Hologram Cloud

AerSale Corp

Bit Digital, Inc

Progenity

Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next GameStop Corp (NYSE: GME) or AMC Entertainment Holdings Inc (NYSE: AMC). A short squeeze can occur when a heavily shorted stock rises in value instead of falling.

5 Short Squeeze Candidates To Watch: Progenity Tops List Again, Augmented Reality Play WiMi Hologram Joins List

Protagonist Therapeutics (PTGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Protagonist Therapeutics (PTGX) to Report a Decline in Earnings: What to Look Out for

NEWARK, Calif., Oct. 26, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that it will receive a $7.5 million milestone payment from Janssen Biotech, Inc. (Janssen) triggered by the completion of the clinical data collection-related Phase 1 activities for PN-235 (JNJ-2113).

Protagonist Therapeutics Earns $7.5 Million Milestone Payment from IL-23 Receptor Collaboration with Janssen

Digital Brands Group Inc

Altimeter Growth

Paltalk

Here are five short squeeze stocks many investors are putting on their radar right now as a result of higher short interest and borrow fees. The post Short Squeeze Stocks: PTGX, AGC and 3 Others Experts Think Are Ready to Pop appeared first on InvestorPlace.

Short Squeeze Stocks: PTGX, AGC and 3 Others Experts Think Are Ready to Pop

5 Short Squeeze Candidates To Watch: Progenity, Digital Brands Top List Again, SPAC AGC Joins Ahead Of Merger

NEWARK, Calif., Oct. 12, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V.

Protagonist Therapeutics to Present at the Jefferies Next Generation IBD Therapeutics Summit

Shares of Protagonist Therapeutics Inc (NASDAQ: PTGX) nearly doubled on Monday as the U.S. FDA said it could resume the clinical trials for Rusfertide – an investigational, injectable hepcidin mimetic. The U.S. FDA had paused the clinical studies last month The drug regulator had paused the clinical studies last month after the use of the […] The post Protagonist Therapeutics shares nearly doubled on Monday: explore why appeared first on Invezz.

Protagonist Therapeutics shares nearly doubled on Monday: explore why

Protagonist Therapeutics (PTGX) stock is rocketing higher on Monday thanks to an update from the FDA concerning rusfertide clinical studies. The post PTGX Stock: The FDA News That Has Protagonist Therapeutics Investors Cheering Today appeared first on InvestorPlace.

PTGX Stock: The FDA News That Has Protagonist Therapeutics Investors Cheering Today

The FDA has removed the full clinical hold on Protagonist Therapeutics Inc's (NASDAQ: PTGX) rusfertide clinical studies. The Company provided the requested individual patient clinical safety reports, updated the investigator brochure and patient informed consent forms.

Protagonist Shares Almost Double As FDA Lifts Clinical Hold On Rusfertide Program

The stock price of Protagonist Therapeutics Inc (NASDAQ: PTGX) increased by over 80% pre-market today. This is why it happened.

PTGX Stock: Why It Substantially Increased Today

Shares of Protagonist Therapeutics Inc. PTGX, +0.72% soared 87.0% in premarket trading on Monday after the company said the Food and Drug Administration had lifted a clinical hold on clinical trials of rusfertide, its experimental blood cancer treatment. The hold was put into place over concerns of skin tumors from animal research and a deeper examination of four new cancer cases that emerged during a clinical trial.

Protagonist Therapeutics shares soar after FDA lifts clinical hold on its experimental cancer drug

NEWARK, Calif., Oct. 11, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that the U.S. Food and Drug Administration (FDA) has removed the full clinical hold on the Company's rusfertide clinical studies, announced on September 17, 2021.

Protagonist Therapeutics Announces Removal of FDA Clinical Hold on the Rusfertide Clinical Development Program

When Wall Street overreacts to a news catalyst, contrarian traders can step in to take advantage of a rare opportunity now with PTGX stock. The post Battered Protagonist Therapeutics Stock Is Primed For a Dip-Buy appeared first on InvestorPlace.

Battered Protagonist Therapeutics Stock Is Primed For a Dip-Buy

NEWARK, Calif., Oct. 4, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that an abstract highlighting new results from its Phase 2 study of rusfertide in hereditary hemochromatosis (HH) has been selected for oral presentation at The Liver Meeting® 2021, hosted by the American Association for the Study of Liver Diseases (AASLD), taking place virtually November 12-15, 2021.

Protagonist Therapeutics Announces Data from Phase 2 Rusfertide Study in Hereditary Hemochromatosis Selected for Oral Presentation at the Annual AASLD Meeting

Today, we revisit Protagonist Therapeutics for the first time in over a year and a half. The stock has cratered in recent trading sessions after the FDA put a clinical hold on a key study.

Protagonist Therapeutics: How To Buy The Dip

NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Protagonist Therapeutics, Inc. (“Protagonist” or the “Company”) (NASDAQ: PTGX) on behalf of Protagonist stockholders. Our investigation concerns whether Protagonist has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. Protagonist Therapeutics is a biopharmaceuti

PROTAGONIST ALERT: Bragar Eagel & Squire, P.C. is Investigating Protagonist on Behalf of Protagonist Stockholders and Encourages Investors to Contact the Firm

Protagonist Therapeutics (PTGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Protagonist Therapeutics (PTGX) Moves 18.2% Higher: Will This Strength Last?

New York, New York--(Newsfile Corp. - September 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") (NASDAQ: PTGX). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Protagonist and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Protagonist Therapeutics, Inc. - PTGX

The FDA has placed a clinical hold on testing of rusfertide.

News for Protagonist Therapeutics Stock (PTGX)